Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label,Phase II Study Evaluating the Efficacy and Safety of Trastuzumab Combined With Oral Chemotherapy or Endocrine Therapy in Patients With HER-2 Positive Stage I Breast Cancer

NCT04383275 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT04383275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04383275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label,Phase II Study Evaluating the Efficacy and Safety of Trastuzumab Combined With Oral Chemotherapy or Endocrine Therapy in Patients With HER-2 Positive Stage I Breast Cancer
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 20, 2020
Completion date
July 6, 2031
Enrollment
367 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer